FindTrial
Sign In

A historical cohort study of efficacy and safety of faecal bacteria transplantation combined with interferon and nucleoside analogs in the treatment of chronic hepatitis B

A historical cohort study of efficacy and safety of faecal bacteria transplantation combined with interferon and nucleoside analogs in the treatment of chronic hepatitis B

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044125
Enrollment
Unknown
Registered
2021-03-11
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic viral hepatitis B

Interventions

faecal bacteria transplantation + interferon + nucleoside analogs:No
faecal bacteria transplantation and nucleoside analogues:No
interferon + nucleoside analogues treatment cohort:No
nucleoside analogues treatment cohort:No

Sponsors

The Fifth Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Chronic hepatitis B patients with antiviral treatment with nucleoside analogues for more than 1 year; (2) Aged >= 18 years; (3) Willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients contraindicated for interferon or faecal bacteria transplantation; (2) Pregnant and lactating women; (3) Diagnosis of HCC within 3 months before enrollment; (4) Life expectancy is less than 1 year; (5) The situation that other researchers think is not suitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
HBsAg titer negative conversion rate;—

Countries

China

Contacts

Public ContactMingxing Huang

The Fifth Affiliated Hospital of Sun Yat-Sen University

Huangmx5@mail.sysu.edu.cn+86 15989778816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026